Auris Medical Holding AG (EARS) reported quarterly earnings results on Wednesday, May-11-2016. The company reported $-0.26 earnings per share for the quarter, missing the analyst consensus estimate by $-0.03. Analysts had a consensus of $-0.23. During the same quarter in the previous year, the company posted $-0.28 EPS.
Auris Medical Holding AG opened for trading at $3.28 and hit $3.85 on the upside on Tuesday, eventually ending the session at $3.53, with a gain of 7.62% or 0.25 points. The heightened volatility saw the trading volume jump to 1,68,210 shares. Company has a market cap of $121 M.
Auris Medical Holding AG is a holding company. The Company is a development-stage biopharmaceutical company. The Company’s advanced product candidate is AM-101 for acute inner ear tinnitus. It is also developing AM-111 for acute inner ear hearing loss. Its product candidates are injected under local anesthesia into the middle ear by a technique called intratympanic or i.t. injection. The Company is also engaged in preclinical studies of AM-102 and AM-123. AM-101 is formulated in a biocompatible gel. AM-111 contains a synthetic D-form peptide (D-JNKI-1) that protects sensorineural structures in the inner ear from stress-induced damage. AM-111 is being developed for the treatment of autoimmune sensorineural hearing loss (ASNHL).